Adjustment of the UKU Side Effect Rating Scale for adults with intellectual disabilities. A pilot study

Tveter, Anne Louise; Bakken, Trine Lise; Bramness, Jørgen G.; Røssberg, Jan Ivar

doi:10.1108/amhid-11-2013-0064

Cited by 7 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difficulties in communication and the introspection characteristics of these patients should be taken into consideration. Tveter, Bakken et al [59] proposed an adjustment of this scale that classified the symptoms regarding observability and difficulty to score for the nurses and experts. Thus, to evaluate the presence of AEs, an adaptation to the UKU Scale for patients with intellectual disabilities was used [58].…”

Section: Adverse Eventsmentioning

confidence: 99%

Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study

de Miguel,

Ballester,

Egoavil

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Introduction: Up to 73% of individuals with autism spectrum disorder (ASD) and intellectual disability (ID) currently have prescriptions for psychotropic drugs. This is explained by a higher prevalence of medical and psychiatric chronic comorbidities, which favors polypharmacy, increasing the probability of the appearance of adverse events (AEs). These could be a preventable cause of harm to patients with ASD and an unnecessary waste of healthcare resources. Objective: To study the impact of pharmacogenetic markers on the prevention of AE appearance in a population with ASD and ID. Methods: This is a cross-sectional, observational study (n = 118, 72 participants completed all information) in the ASD population. Sociodemographic and pharmacological data were gathered. The Udvalg for Kliniske Undersøgelser Scale (UKU Scale) was used to identify AEs related to the use of psychotropic medication. Polymorphisms of DOP2, ABCB1, and COMT were genotyped and correlated with the AE to find candidate genes. Furthermore, a review of all medications assessed in a clinical trial for adults with autism was performed to enrich the search for potential pharmacogenetic markers, keeping in mind the usual medications. Results: The majority of the study population were men (75%) with multiple comorbidities and polypharmacy, the most frequently prescribed drugs were antipsychotics (69%); 21% of the participants had four or more AEs related to psychotropic drugs. The most common were “Neurological” and” Psychiatric” (both 41%). Statistical analysis results suggested a significant correlation between the neurological symptoms and the DOP2 genotype, given that they are not equally distributed among its allelic variants. The final review considered 19 manuscripts of medications for adults with ASD, and the confirmed genetic markers for those medications were consulted in databases. Conclusion: A possible correlation between neurologic AEs and polymorphisms of DOP2 was observed; therefore, studying this gene could contribute to the safety of this population’s prescriptions. The following studies are underway to maximize statistical power and have a better representation of the population.

show abstract

Section: Adverse Eventsmentioning

confidence: 99%

Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study

de Miguel,

Ballester,

Egoavil

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

The Treatment of the Dually Diagnosed: Intellectual Disability and Severe Psychopathology

McPherson¹,

Colon

Scott

2020

Handbook of Dual Diagnosis

View full text Add to dashboard Cite

Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review

Kelly

Kilmartin

Lannon

et al. 2022

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose Intellectual disability (ID) is a chronic neurodevelopmental condition characterised by limitations in intelligence and adaptive skills with an onset prior to the age of 18 years. People with ID have complex healthcare needs and are more likely than the general population to experience multiple comorbidities and polypharmacy, with subsequent increased risk of adverse medication effects. The aim of this scoping review is to characterise rating scales used to measure adverse effects of medication in people with ID. Methods Four online databases (PsycINFO, Medline, Web of Science and OpenGrey) were searched in April 2020. Studies were assessed for inclusion against pre-specified eligibility criteria. Reference lists of included studies were hand searched. Data extraction was carried out by two independent reviewers and key findings were tabulated for consideration. Studies were assessed for quality using the Mixed Methods Appraisal Tool. Results The search resulted in 512 unique records, of which fifteen met the inclusion criteria. Fourteen scales were identified. All scales assessed adverse effects of psychotropics only. Of the scales, only one, the Matson Evaluation of Drug Side Effects, which focuses on psychotropic medications, was originally developed for use in a population with ID. Conclusion The Matson Evaluation of Drug Side Effects scale appears to be the most reliable and well-researched scale in people with ID. However, a scale which measures adverse effects across multiple medication classes would be valuable for use in this population.

show abstract

Adjustment of the UKU Side Effect Rating Scale for adults with intellectual disabilities. A pilot study

Cited by 7 publications

References 29 publications

Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study

Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study

The Treatment of the Dually Diagnosed: Intellectual Disability and Severe Psychopathology

Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review

Contact Info

Product

Resources

About